SCV-07 works by stimulating the immune system through its effects on T-helper 1 cells, which are essential for clearance of viral infections.
The trial found the treatment to be safe and that it led to circulating plasma concentrations similar to those obtained in previous phase I studies using a subcutaneous injection of SCV-07. Importantly, SCV-07 taken orally resulted in only 10% plasma level variability between all volunteers in this study, demonstrating highly predictable plasma concentrations after oral dosing of this drug.
“We are pleased by these data demonstrating SCV-07’s oral availability, highly predictable plasma concentrations, and minimal variability among volunteers,” said Dr Cynthia Tuthill, chief scientific officer and senior vice president of Scientific Affairs at SciClone Pharmaceuticals.
“These results provide us with a solid platform from which to compare different dosing regimes in future human studies, and to evaluate alternate indications in our ongoing animal model studies.”
SciClone acquired exclusive worldwide rights, outside of Russia, to SCV-07 from St. Petersburg-based Verta.